2021
DOI: 10.1107/s1600577520016811
|View full text |Cite
|
Sign up to set email alerts
|

Study of the X-ray radiation interaction with a multislit collimator for the creation of microbeams in radiation therapy

Abstract: Microbeam radiation therapy (MRT) is a developing radiotherapy, based on the use of beams only a few tens of micrometres wide, generated by synchrotron X-ray sources. The spatial fractionation of the homogeneous beam into an array of microbeams is possible using a multislit collimator (MSC), i.e. a machined metal block with regular apertures. Dosimetry in MRT is challenging and previous works still show differences between calculated and experimental dose profiles of 10–30%, which are not acceptable for a clin… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
2

Citation Types

1
9
0
1

Year Published

2021
2021
2025
2025

Publication Types

Select...
7

Relationship

0
7

Authors

Journals

citations
Cited by 14 publications
(11 citation statements)
references
References 54 publications
1
9
0
1
Order By: Relevance
“…The source replication approach used in penMRT accelerates the simulations with the cost of neglecting the transmission, diffusion, and reflection through the MSC. In a recent study from Pellicioli et al 59 . the effect of the MSC on peak and valley doses has been investigated.…”
Section: Discussionmentioning
confidence: 99%
See 1 more Smart Citation
“…The source replication approach used in penMRT accelerates the simulations with the cost of neglecting the transmission, diffusion, and reflection through the MSC. In a recent study from Pellicioli et al 59 . the effect of the MSC on peak and valley doses has been investigated.…”
Section: Discussionmentioning
confidence: 99%
“…The source replication approach used in penMRT accelerates the simulations with the cost of neglecting the transmission, diffusion, and reflection through the MSC. In a recent study from Pellicioli et al 59 the effect of the MSC on peak and valley doses has been investigated. Based on this study, a perfect collimator assumption might cause an underestimation of the valley doses from 5% to 30% depending on the field size and the energy spectrum.The peak doses might be less affected with an underestimation of about 0.2%.…”
Section: Discussionmentioning
confidence: 99%
“…Typical photon energies in synchrotron beams dedicated to biomedical applications range from approximately 10 to 150 keV. Currently, many synchrotron facilities operate with an electron beam energy greater than or equal to 2.4 GeV and high electron-beam currents are achievable in the accelerator ring of third-and fourth-generation synchrotrons, which include the Australian Synchrotron (AS) in Melbourne, the National Synchrotron Light Source (NSLS) in Brookhaven, USA and the European Synchrotron Radiation Facility (ESRF) in Grenoble, France, [1][2][3]. A table summarizing third-and fourth-generation synchrotrons around the world housing beamlines capable of conducting radiobiological and clinical research is presented in Supplementary data (Section S1).…”
Section: Introductionmentioning
confidence: 99%
“…(i) the standard MRT configuration used for rodent experiments for many years has an average energy of 104.2 KeV and a peak energy of 87.7 keV, (ii) the preclinical MRT configuration developed for veterinary trials and has a mean energy of 119 KeV and a peak energy of 102.1 KeV, and/or (iii) the clinical MRT configuration for future clinical applications with a mean energy of 122.8 KeV and a peak energy of 108.2 KeV [3,13].…”
mentioning
confidence: 99%
“…RIBE is thought to be transmitted via gap-junction intercellular communication (7), or extracellular soluble factors (8). X-ray beams produced by the third-generation synchrotron source such as Australian Synchrotron (AS) in Melbourne, Australia and the first fourthgeneration European Synchrotron Radiation Facility (ESRF) in Grenoble, France, have the advantage of delivering high radiation doses to a very small volume with low beam divergence (9,10). These features facilitate the study of in vitro and in vivo non-targeted effects.…”
Section: Introductionmentioning
confidence: 99%